Current factor IX replacement options for hemophilia B and the challenges ahead.

Massimo FranchiniMarco ZaffanelloDaniele Focosi

Published in: Expert opinion on pharmacotherapy (2023)

The recent introduction of recombinant EHL FIX products has represented a major advance in the therapeutic management of hemophilia B patients, permitting both a reduction of treatment burden and improving patients' compliance to prophylaxis and, ultimately, quality of life.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
risk factors
smoking cessation